Last updated on February 2018

Ketogenic Diet in Infants With Epilepsy (KIWE)


Brief description of study

Epilepsy, a condition where individuals are prone to recurrent epileptic seizures, is the most common chronic neurological disorder in children. Epilepsy onset is most common in the first two years of life and is associated with poor prognosis for seizure control and neurodevelopmental outcome.

The ketogenic diet (KD) is a medically supervised diet that is high in fat and restricted in carbohydrates and protein. KD therapy has shown to be an effective treatment for seizures in children with epilepsy older than two. Associated benefits include: a reduced requirement for routine and emergency antiepileptic drugs (AED) and fewer seizure related hospital admissions. Although reports suggest that KD therapy improves seizures in younger children there is no high quality trial data that demonstrates effectiveness and safety in this age group. The KD is resource intensive, requiring dietetic and physician time; data is required to justify expansion of services to cater for the apparent need.

The investigators therefore propose a prospective multicentre randomised trial to investigate the effectiveness and safety of the KD in children with epilepsy under the age of 2, who have failed to respond to two or more AEDs. Children will be randomly assigned to either receive the KD or further AEDs. The allocated treatment will be started after a 2week baseline period, and it's effectiveness assessed after 8 weeks. Seizure diaries will be used to record seizures and related events, a questionnaire will be used to assess diet tolerance; also growth and blood biochemistry will be monitored.

The information obtained from this study is necessary to optimise choices in epilepsy treatment, aiming to improve outcomes and thus determine whether and when the KD should should be used.

Detailed Study Description

The project proposed is a randomised controlled multicentre study of infants with epilepsy who have failed to respond to two or more pharmacological treatments (antiepileptic drugs (AEDs) or corticosteroids), comparing ketogenic diet to treatment with a further AED.

Children for this study will be recruited from 8 paediatric neurology centres in the South of England who have an established KD service for children with epilepsy. The collaborating paediatric neurologists based in these centres are named co-applicants on this proposal. All children ages 3 to 24 months will be considered if they have a diagnosis of epilepsy, namely continuing seizures despite a trial of 2 or more AEDs (including corticosteroids) and are experiencing at least 8 seizures a week.

Children will be excluded if they are shown to have: a metabolic disease contradicting the use of KD; a progressive neurological disease; severe gastrooesophageal reflux or have undergone a previous failed trial of KD. In addition, families should be able to attend clinic on the required timeline. KD meal plans will be accurately calculated for each child individually by a dietitian with consideration of daily calorie requirements, fat to carbohydrate ratio (3:1 or 4:1), adequate protein intake and vitamin and mineral supplementation. Ongoing adjustments to the diet by the dietitian are determined by weight gain and the degree of ketosis.

  1. Baseline assessment: Written consent will be obtained from eligible children. Full history including seizure type, neurological examination, weight, length and head circumference will be documented. Randomisation to KD or standard AED group will be carried out with the support of the UCL PRIMENT Clinical Trials Unit (CTU).
     Investigations to be performed in the KD group (or if clinically indicated in the AED
     group) will include FBC, U&Es, Glucose, LFTs, Calcium, Magnesium, Phosphate, Zinc,
     Selenium, Acylcarnitine profile, Cholesterol, Triglycerides, Urate, 25 hydroxy Vitamin
     D, urine calcium/creatinine, urine organic acids. An EEG will be performed if clinically
     indicated.

2. Observation period of 2 weeks: No changes of regular AEDs. Emergency seizure treatments

     will continue as required( acute treatment with benzodiazepines). The following data
     will be recorded in a standardized diary (these data will continue to be recorded
     throughout the intervention period of 8 weeks): seizure types, seizure frequency, number
     of emergency seizure treatments required, contacts with the NHS due to seizure
     exacerbation (hospital admissions number of days, A&E and or GP attendances)

3. Start of the classical KD or further AED. The classical KD will be administered as per

     protocol of the treating service. The recording of seizure types and frequency is to be
     continued.

4. Second Assessment (4 weeks after the start of the treatment period, all patients):

     clinical review including weight; documentation of seizure frequency, and tolerability
     of the diet in randomised KD group by questionnaire.

5. Third/final assessment (8 weeks after starting treatment/all patients). Clinical review

     including neurological examination, weight, length and head circumference. Documentation
     of seizure outcome (from seizure diaries). KD group only: completion of tolerability
     questionnaire, blood investigations (FBC, U&Es, Glucose, LFTs, plasma bicarbonate,
     calcium, magnesium, phosphate, zinc, selenium, acylcarnitine profile, cholesterol,
     triglycerides, urate, nonesterified fatty acids, blood ketones) and urine
     calcium/creatinine ratio. EEG will be performed if clinically indicated.

Dependent on seizure response, KD (diet group) or AED (standard AED group) will then be continued or changed. Those in the AED group of failed will be offered KD outside the context of the trial. It would be anticipated that clinical data would be collected on all patients to 12 months to determine retention rates.

Exit criteria: Children will withdraw from the treatment prior to 8 weeks should there be q >50% increase in seizure frequency from the baseline, or if intolerable side effects are not resolved by manipulation of KD or medication. A safety monitoring committee will be convened.

Clinical Study Identifier: NCT02205931

Contact Investigators or Research Sites near you

Start Over

Shakti Agrawal, MBBS

Birmingham Children's Hospital
Birmingham, United Kingdom
  Connect »

Andrew Mallick

Bristol Royal Hospital for Children
Bristol, United Kingdom
  Connect »

Alasdair Parker, MA

Addenbrooke's Hospital
Cambridge, United Kingdom
  Connect »

Helen Basu

Lancashire Teaching Hospitals NHS Foundation Trust
Lancashire, United Kingdom
  Connect »

Helen McCullagh, RCPCH

Leeds Teaching Hospital
Leeds, United Kingdom
  Connect »

Rachel Kneen, BMBS

Alder Hey Children's Hospital
Liverpool, United Kingdom
  Connect »

Christin Eltze, MD Res

Great Ormond Street Hospital
London, United Kingdom
  Connect »

Penny Fallon

St George's University Hospitals NHS Foundation Trust
London, United Kingdom
  Connect »

Tim Martland, RCPCH

Royal Manchester Children's Hospital
Manchester, United Kingdom
  Connect »

Anita Devlin

The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
  Connect »

Archana Desurkar

Sheffield Children's NHS Foundation Trust
Sheffield, United Kingdom
  Connect »